METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY

• US 20120269863A1
• Filed: 04/25/2012
• Published: 10/25/2012
• Est. Priority Date: 11/30/1999
• Status: Abandoned Application

• Current Assignee: Curis, Inc.
• Original Assignee: Curis, Inc.
• Inventors: Crompton, Tessa
• Application Number:
  US13/455,887
• Publication Number:
  US 20120269863A1
• Time in Patent Office: Days
• US Class Current: 424/278.1
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 37/04 Immunostimulants

Abstract

The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. The invention provides a method to promote T lymphocyte development using low dose Hedghog, and a method to inhibit T lymphocyte development using high dose Hedgehog. Certain aspects of the invention are directed to preparations of hedgehog polypeptides, agonists, antagonists, or other molecules which regulate patched or smoothened signalling, and their uses as immunomodulatory agents.

Claims

1-42. -42. (canceled)

43. A method for promoting thymic T cell maturation in an animal in need thereof, comprising administering to said animal a hedgehog (HH) antagonist in an amount sufficient to promote T cell maturation in the thymus of said animal, whereby said antagonist promotes T cell maturation in the thymus;

and wherein said HH antagonist is selected from (i) a polypeptide having an amino acid sequence which is at least 90% identical to any one of SEQ ID NOs;

10-18, wherein the polypeptide binds to a patched protein but does not promote hedgehog signaling;

(ii) an antisense construct capable of inhibiting expression of a peptide selected from the group consisting of;

Dhh, Shh, Ihh, Thh, smoothened, and Gli;

or (iii) a small organic molecule, which small organic molecule is a steroidal alkaloid.

44. The method of claim 43, wherein the HH antagonist is a polypeptide having an amino acid sequence which is at least 90% identical to any one of SEQ ID NOs:

10-18, wherein the polypeptide binds to a patched protein but does not promote hedgehog signaling, and wherein binding of the polypeptide to the patched protein disrupts the binding of a hedgehog polypeptide with a hedgehog receptor.

45. The method of claim 43, wherein the HH antagonist is an antisense construct capable of inhibiting expression of a peptide selected from the group consisting of:

Dhh, Shh, Ihh, Thh, smoothened, and Gli.

46. The method of claim 43, wherein the HH antagonist is a small organic molecule, which small organic molecule is a steroidal alkaloid.

47. The method of claim 46, wherein the steroidal alkaloid is a veratrum-type steroidal alkaloid.

48. The method of claim 46, wherein the steroidal alkaloid is cyclopamine or jervine.

49. The method of claim 43, wherein administration of said hedgehog antagonist reduces hedgehog signaling to a level that is sufficient for T cell maturation in the thymus.

50. The method of claim 46, wherein administration of said hedgehog antagonist reduces hedgehog signaling to a level that is sufficient for T cell maturation in the thymus.

51. The method of claim 43, wherein said hedgehog antagonist is administered directly and locally to the thymus of said animal.

52. The method of claim 46, wherein said hedgehog antagonist is administered directly and locally to the thymus of said animal.